Recommendations and expert opinion on the adjuvant treatment of colon cancer in Spain

• Autores: José María Viéitez de Prado, Rocío García Carbonero, Jorge Aparicio Urtasun, Jaime Feliu Batlle, E. González Flores, Enrique Grande Pulido, M. Teresa Pérez Hoyos, Antonieta Salud, Esperanza Torres Sánchez, María Valero, Manuel Valladares Ayerbes, Eduardo Díaz-Rubio García
• Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 13, Nº. 11, 2011, págs. 798-804
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Dialnet Métricas: 1 Cita
• Resumen

  • Adjuvant chemotherapy is the current standard in the management of patients with localised colon cancer (CC) following curative resection. The use of oxaliplatin plus 5 fluorouracil/leucovorin (FOLFOX) or oxaliplatin plus capecitabine-based (XELOX) regimens, both approved in Europe as adjuvant treatment for stage III CC, has improved prognosis in this stage, but questions on their usefulness in high-risk stage II or elderly CC patients and on the role of some prognostic biomarkers are still pending. In April 2010, a consensus meeting on adjuvant CC treatment based on a revision of the most recent literature was held in Spain. The panel considered the use of adjuvant chemotherapy for high-risk stage II CC patients to be justified. Additionally, the more convenient administration of oral fluoropyrimidines vs. IV continuous infusion 5-FU would make XELOX a more suitable alternative for the patient. A more cautious decision should be taken when prescribing oxaliplatin treatment in patients aged ?70.